RapidInformationonOLMNo8.docVIP

PAGE  PAGE 6 Rapid Information on Olmesartan and other ARBs No.208 2014/02/05 　　　　　　　　　　　　　　　　　 　　　　　　　　　Be the first to know! 　　　 　 　　 (Toru Komai, Ph.D.) 208-1: Olmesartan may represent an effective alternative to ACE-inhibitors among first-line drug treatments for hypertension in older people. (Review) Title：Olmesartan vs. Ramipril in Elderly Hypertensive Patients: Review of Data from Two Published Randomized, Double-Blind Studies. 2-3 208-2: Olmesartan potentiated the anti-angiogenic effect of sorafenib through inhibition of IGF-I, VEGF and their receptors, leading to greater anti-tumor activity. The anti-angiogenic effect of olmesartan was partially mediated through the 　　　Ang (1-7). Title：Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlichs Ascites Carcinoma: Role of Angiotensin (1-7). 3-4 208-3: Azelnidipine decreased the serum uric acid levels and the urinary uric acid to creatinine ratio (Uur/Ucr), but not the uric acid clearance to creatinine clearance ratio (Cur/Ccr). Title：Effects of azelnidipine on uric acid metabolism in patients with essential hypertension. 4-5 Abbreviations: BP: blood pressure, SBP/DBP: systolic/ diastolic BP, RAS: renin–angiotensin system, AT1 Receptor: angiotensin II type 1 receptor, Ang II: angiotensin II, ARB: angiotensin II receptor blocker, ACE-inhibitor: angiotensin converting enzyme inhibitor, CCB: calcium channel blocker, 208-1: Olmesartan may represent an effective alternative to ACE-inhibitors among first-line drug treatments for hypertension in older people. (Review) Hypertension (≥140/90mmHg) has an estimated prevalence of approximately 55 % in men and 62 % in women over 65 years in the worldwide population. One of the primary causes of BP elevation in the elderly is increased arterial stiffness, caused by age